Takeda announces positive results for mezagitamab in Phase 2 ITP study

Pallavi Madhiraju- March 14, 2024 0

Takeda Pharmaceutical Company Limited has disclosed favorable top-line outcomes from a Phase 2, randomized, double-blind, placebo-controlled trial, assessing the safety, tolerability, and efficacy of mezagitamab ... Read More

Oscotec reports positive results from cevidoplenib phase 2 trial in ITP

Pallavi Madhiraju- February 24, 2023 0

Oscotec has reported positive results from the phase 2 clinical trial of its SYK inhibitor cevidoplenib in patients with immune thrombocytopenia (ITP) who did not ... Read More

Sobi begins avatrombopag phase 3 trial in immune thrombocytopenia in pediatrics

pallavi123- March 14, 2021 0

Swedish Orphan Biovitrum (Sobi) said that the first patient has been dosed with Doptelet (avatrombopag) in a phase 3 trial for the treatment of immune ... Read More

FDA greenlights Amgen’s Nplate for pediatric immune thrombocytopenia

pharmanewsdaily- December 16, 2018 0

Amgen’s Nplate (romiplostim) has received US Food and Drug Administration (FDA) approval for treating pediatric patients with immune thrombocytopenia (ITP). This latest approval extends the ... Read More